<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04714814</url>
  </required_header>
  <id_info>
    <org_study_id>Metastatic CRC cell fate</org_study_id>
    <nct_id>NCT04714814</nct_id>
  </id_info>
  <brief_title>Mechanisms of Fate Evolution of Colorectal Adenocarcinoma Metastasis</brief_title>
  <official_title>a Multi-omics Cohort Study of Mechanisms of Fate Evolution of Colorectal Adenocarcinoma Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Minimally Invasive Surgery Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Science and Technology Commission of Shanghai Municipality</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Minimally Invasive Surgery Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two stage nested case-control study to construct the hologram plane , explore&#xD;
      biomarkers and screening original drugs of metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stage Ⅰ is a cross-sectional study to record selected information and biospecimen of more&#xD;
      than 200 colorectal cancer cases( at least 160 stage Ⅲ cases,40 stage Ⅳ（synchronous&#xD;
      metastasis）).Stage Ⅱ is a nested case-control study. 200 eligible cases enrolled in&#xD;
      phaseⅠwill be followed up for 5 years to record recurrence, metastasis and to collect&#xD;
      biospecimen . Each case with the study outcome will be matched with the corresponding control&#xD;
      according to the proportion of 1:1 according to age, sex and other conditions, and further&#xD;
      analysis will be made.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>recurrence or metastasis provened by imageologic diagnosis (PFS)</measure>
    <time_frame>May 31, 2023</time_frame>
    <description>tumor metastasis or progression occurred during the enrolment period</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Colorectal Cancer Stage III</condition>
  <condition>Colorectal Cancer Stage IV</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      tissue samples, blood samples, stool, pleural effusion&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The patients with CRC (Stage III and Stage IV)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Baseline population (stage III colorectal cancer) inclusion criteria:&#xD;
&#xD;
               1. Aged 18-75.&#xD;
&#xD;
               2. Physical condition (ECOG) score ≤ 1.&#xD;
&#xD;
               3. Colorectal adenocarcinoma was confirmed by histopathology.&#xD;
&#xD;
               4. No family history of hereditary tumor.&#xD;
&#xD;
               5. Accept standard radical resection of colorectal cancer, R0 resection, number of&#xD;
                  lymph node dissection ≥ 12.&#xD;
&#xD;
               6. Preoperative clinical stage is stage III.&#xD;
&#xD;
               7. Agree to receive standard fluorouracil ±oxaliplatin adjuvant chemotherapy for 3&#xD;
                  to 6 months.&#xD;
&#xD;
               8. Enough primary surgical or biopsy tissues for examination.&#xD;
&#xD;
               9. Enough peripheral blood samples for examination.&#xD;
&#xD;
              10. Agree to sign informed consent to participate in this project.&#xD;
&#xD;
        Baseline population (stage Ⅳ colorectal cancer) inclusion criteria:&#xD;
&#xD;
          1. Aged 18-75.&#xD;
&#xD;
          2. Histopathological diagnosed colonic or rectal adenocarcinoma of stage IV.&#xD;
&#xD;
          3. Not yet received antineoplastic therapy.&#xD;
&#xD;
          4. Baseline imaging evaluation shows at least one measurable focus.&#xD;
&#xD;
          5. Sufficient primary surgical or biopsy tissues and metastatic tissues of at least one&#xD;
             organ for examination.&#xD;
&#xD;
          6. Enough peripheral blood samples for examination.&#xD;
&#xD;
          7. Expected survival time ≥ 3 months.&#xD;
&#xD;
          8. Provide information such as demography, current medical history or current tumor&#xD;
             disease, pathological diagnosis and staging of tumor, physical status of ECOG,&#xD;
             radiographic evaluation of tumor, etc.&#xD;
&#xD;
          9. Agree to sign informed consent to participate in this project.&#xD;
&#xD;
        Metastasis colorectal cancer cohort study inclusion criteria:&#xD;
&#xD;
          1. Aged 18-75.&#xD;
&#xD;
          2. Physical condition (ECOG) score ≤ 1.&#xD;
&#xD;
          3. Colorectal adenocarcinoma was confirmed by histopathology.&#xD;
&#xD;
          4. No family history of hereditary tumor.&#xD;
&#xD;
          5. Accept standard radical resection of colorectal cancer, R0 resection, number of lymph&#xD;
             node dissection ≥ 12.&#xD;
&#xD;
          6. Preoperative clinical stage is stage III and the postoperative pathological stage was&#xD;
             confirmed as stage III.&#xD;
&#xD;
          7. Agreed to receive standard fluorouracil ±oxaliplatin adjuvant chemotherapy for 3 to 6&#xD;
             months.&#xD;
&#xD;
          8. Enough primary surgical or biopsy tissues for examination.&#xD;
&#xD;
          9. Enough peripheral blood samples for examination.&#xD;
&#xD;
         10. Agree to sign informed consent to participate in this project.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Baseline population (stage III colorectal cancer) exclusion criteria:&#xD;
&#xD;
               1. Participating in interventional clinical studies or receiving research treatments&#xD;
                  that influence patients' treatment decisions.&#xD;
&#xD;
               2. Postoperative pathological stage was confirmed as stage II.&#xD;
&#xD;
               3. Abnormal function of heart, lung, liver, kidney, hematopoiesis or bone marrow&#xD;
                  reserve, which cannot tolerate operation or chemotherapy.&#xD;
&#xD;
               4. Diagnosed with malignant tumors that have progressed or need to be treated in the&#xD;
                  past 5 years, except for cured skin basal cells and skin squamous cell carcinoma.&#xD;
&#xD;
               5. Having mental illness or other serious cardiovascular diseases.&#xD;
&#xD;
               6. Pregnancy or lactation or planned pregnancy within one year.&#xD;
&#xD;
               7. Emergency operation (perforation, bleeding, intestinal obstruction, etc.).&#xD;
&#xD;
        Baseline population (stage Ⅳcolorectal cancer) exclusion criteria:&#xD;
&#xD;
          1. Family history of hereditary colorectal cancer, such as Lynch syndrome, familial&#xD;
             adenomatous polyposis, P-J syndrome, etc.&#xD;
&#xD;
          2. Nervous system metastasis.&#xD;
&#xD;
          3. Complicated with other malignant tumors.&#xD;
&#xD;
          4. Having poorly controlled chronic concomitant diseases that affect the prognosis.&#xD;
&#xD;
          5. Any complication that may affect the results of the study .&#xD;
&#xD;
        Metastasis colorectal cancer cohort study exclusion criteria:&#xD;
&#xD;
          1. Participating in interventional clinical studies or receiving research treatments that&#xD;
             influence patients' treatment decisions.&#xD;
&#xD;
          2. Abnormal function of heart, lung, liver, kidney, hematopoiesis and bone marrow&#xD;
             reserve, which cannot tolerate operation and chemotherapy.&#xD;
&#xD;
          3. Diagnoses with malignant tumors that have progressed or need to be treated in the past&#xD;
             5 years, except for cured skin basal cells and skin squamous cell carcinoma.&#xD;
&#xD;
          4. Having mental illness or other serious cardiovascular disease.&#xD;
&#xD;
          5. Pregnancy or lactation or planned pregnancy within one year.&#xD;
&#xD;
          6. Emergency operation (perforation, bleeding, intestinal obstruction, etc.).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sun Jing, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sun Jing, PhD</last_name>
    <phone>13524284622</phone>
    <email>sj11788@rjh.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Ruijin Hospttal</name>
      <address>
        <city>Shanghai</city>
        <state>Sahgnhai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanye Yang, Bachelor</last_name>
      <phone>+86-13636419858</phone>
      <email>young0503@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal , Metastatisis ,Cancer Cell Fate Regulatory Mechanism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

